MPG.eBooks - Description: CADTH Canadian Drug Expert Committee recommendation: AbobotulinumtoxinA (Dysport therapeutic -- Ipsen Biopharmaceuticals Canada Inc.)

Cover Image

Read Now

CADTH Canadian Drug Expert Committee recommendation: AbobotulinumtoxinA (Dysport therapeutic -- Ipsen Biopharmaceuticals Canada Inc.) indication: for the symptomatic treatment of focal spasticity affecting the upper limbs in adults

The CADTH Canadian Drug Expert Committee (CDEC) recommends that abobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) be reimbursed for the symptomatic treatment of focal spasticity affecting the upper limbs in adults

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2017, October 2017
Edition:	Version 1.0
Series:	CADTH common drug review
Subjects:	Canada Muscle Spasticity / Drug Therapy Cost-benefit Analysis Upper Extremity / Physiopathology Insurance, Health, Reimbursement / Economics Drug Costs Botulinum Toxins, Type A / Therapeutic Use
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK534677
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The CADTH Canadian Drug Expert Committee (CDEC) recommends that abobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) be reimbursed for the symptomatic treatment of focal spasticity affecting the upper limbs in adults
Item Description:	"Final."
Physical Description:	1 PDF file (7 pages)